API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.prnewswire.com/news-releases/everest-medicines-announces-china-center-for-drug-evaluation-of-nmpa-recommends-priority-review-for-cefepime-taniborbactam-for-the-treatment-of-complicated-urinary-tract-infections-including-pyelonephritis-301932731.html
https://www.prnewswire.com/news-releases/everest-medicines-partner-venatorx-receives-fda-acceptance-and-priority-review-of-new-drug-application-for-cefepime-taniborbactam-to-treat-complicated-urinary-tract-infections-cuti-301900949.html
https://www.prnewswire.com/news-releases/everest-medicines-announces-that-licensing-partner-venatorx-pharmaceuticals-reports-positive-results-from-pivotal-phase-3-cefepime-taniborbactam-trial-301499929.html
https://www.businesswire.com/news/home/20201021005639/en/Venatorx-Pharmaceuticals-to-Present-Data-on-Cefepime-Taniborbactam-at-IDWeek-2020